

COVID-19, Acute Lymphoblastic Leukemia and Down Syndrome: A Short Review and a Case Report

Ahmed Arafat, M.D., Ph.D. ^{1*}, Sadykova D.I.¹ M.D., Ph.D., Ayrat Ziatdinov¹ M.D., Ph.D.,
Svetlana Senek¹ M.D., Ph.D., Natalya Samoilova¹ M.D., Ph.D., Tamara Makarova¹ M.D., Ph.D.

The first and second authors contributed equally to this work.

1. Kazan State Medical University, Kazan, Russian Federation

Children's Republican Clinical Hospital, Kazan, Russian Federation

*Corresponding Author

Table 1. Laboratory results upon discharge from the hospital:

IgG	C3	C4	IgA	WBC	Segs	Ly	HGB	PLT	Fibrinogen	PTI	INR	AST	ALT	Urea	Creatinine	CRP
6.86	118	39	0.6	6,22			118	243				37	28	3.5		
g/L	mg/dL	mg/dL	g/L	k	51%	27%	g/L	k/μL	2.2 g/l	56.6%	1.37	IU/L	IU/L	Mmol/L	37 μmol/L	0.35
																mg/L
k= thousand, Segs= segmented neutrophils, Ly= Lymphocytes, HGB= Hemoglobin, PLT= Platelets, PTI= Prothrombin index, INR=international normalized ratio, AST= Aspartate transaminase, ALT= Alanine transaminase, CRP=C-reactive protein																

Table 2. Treatment and Outcome Timeline:

Day of admission	Treatment			CRP (mg/L)	PCR results for COVID-19	Clinical condition
	Hydroxychloroquine and Azithromycin	Meropenem	Tocilizumab			
1 st - 7 th				Irrelevant	-ve	Stable
8 th - 13 th	From 8 th till 12 th	Started on 8 th		↑0.18- 0.56	+ve on 12 th	Fever, consolidations, GGO in CT
14 th - 19 th		Till 18 th		↑↑2.31- 4.8	+ve on 14 th	Fever, ↑ consolidations, GGO in CT
20 th -26 th			Single dose on 20 th	↓↓4- 0.35	-ve on 24 th and 26 th	Stable, clear chest on auscultation
CRP= C-reactive protein, PCR= polymerase chain reaction, -ve= negative, +ve=positive, GGO= ground-glass opacities, CT= computed tomography.						